Himadri Speciality Chemical Ltd Honoured with the Golden Peacock Award for Occupational Health & Safety 2025
KOLKATA, India, July 10, 2025 /PRNewswire/ -- Himadri Speciality Chemical Ltd has…
Euro NCAP highlights safety flaws in new models as five cars secure top ratings
LEUVEN, BELGIUM – Since publishing its first crash test results in 1997,…
Euro NCAP to Launch New Round of 2025 Safety Results
WhatLatest Euro NCAP safety results published online and via social media.WhenWednesday 9…
FIS continues commitment to Para events safety and accessibility with annual site visits
Jul 02, 2025 - Every year, generally towards the back end of the…
100 Years of DEKRA: Safety in a Changing World
Expert Organization Celebrates Centennial STUTTGART, Germany, June 30, 2025 /PRNewswire/ -- Today…
2025 Kia K4 earns 2025 IIHS TOP SAFETY PICK+ award
The 2025 Kia K4 has been awarded the Insurance Institute for Highway…
Huawei Digital Power Hosts the Grid Forming & ESS Safety Forum for Innovative Business Strategies and Safety Ecosystem
SHANGHAI, June 23, 2025 /PRNewswire/ -- On June 12, 2025, Huawei Digital…
Safety Under Pressure: Chery Battery Faces Indonesian Ocean for 53+Hours – Still Running
JAKARTA, Indonesia, June 20, 2025 /PRNewswire/ -- On June 17, Chery commenced the…
Hyundai Motor Group Tops Rankings in 2025 IIHS Top Safety Awards
Hyundai Motor Group Earns 15 IIHS Top Safety Awards Across Hyundai, Kia…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
